DK3497132T3 - Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab - Google Patents

Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab Download PDF

Info

Publication number
DK3497132T3
DK3497132T3 DK17768863.7T DK17768863T DK3497132T3 DK 3497132 T3 DK3497132 T3 DK 3497132T3 DK 17768863 T DK17768863 T DK 17768863T DK 3497132 T3 DK3497132 T3 DK 3497132T3
Authority
DK
Denmark
Prior art keywords
ofatumumab
regimes
methods
multiple sclerosis
treating multiple
Prior art date
Application number
DK17768863.7T
Other languages
English (en)
Inventor
Erik Wallström
Praz Marina Savelieva
Weisskopf Algirdas Jonas Kakarieka
Joseph Michael Kahn
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3497132T3 publication Critical patent/DK3497132T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
DK17768863.7T 2016-08-15 2017-08-11 Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab DK3497132T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662374986P 2016-08-15 2016-08-15
PCT/IB2017/054909 WO2018033841A1 (en) 2016-08-15 2017-08-11 Regimens and methods of treating multiple sclerosis using ofatumumab

Publications (1)

Publication Number Publication Date
DK3497132T3 true DK3497132T3 (da) 2020-09-07

Family

ID=59901554

Family Applications (2)

Application Number Title Priority Date Filing Date
DK20180938.1T DK3733712T3 (da) 2016-08-15 2017-08-11 Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab
DK17768863.7T DK3497132T3 (da) 2016-08-15 2017-08-11 Regimer og fremgangsmåder til behandling af multipel sclerose under anvendelse af ofatumumab

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK20180938.1T DK3733712T3 (da) 2016-08-15 2017-08-11 Programmer og fremgangsmåder til behandling af multipel sklerose under anvendelse af ofatumumab

Country Status (24)

Country Link
US (5) US11161909B2 (da)
EP (5) EP3497132B1 (da)
JP (2) JP6851391B2 (da)
KR (2) KR20200136503A (da)
CN (5) CN120000782A (da)
AU (2) AU2017311664C1 (da)
CA (2) CA3030530C (da)
CY (1) CY1123350T1 (da)
DE (1) DE202017007542U1 (da)
DK (2) DK3733712T3 (da)
ES (2) ES2954259T3 (da)
FI (1) FI3733712T3 (da)
HR (2) HRP20230894T1 (da)
HU (2) HUE063625T2 (da)
IL (4) IL302488B2 (da)
LT (2) LT3733712T (da)
MX (1) MX388593B (da)
PL (2) PL3497132T3 (da)
PT (2) PT3733712T (da)
RS (2) RS60807B1 (da)
RU (1) RU2749951C2 (da)
SI (2) SI3497132T1 (da)
TW (1) TWI752995B (da)
WO (1) WO2018033841A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
EP4707302A2 (en) * 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4816401A (en) 1985-09-09 1989-03-28 University Of Rochester Serum free cell culture medium
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US20020064823A1 (en) 2000-03-30 2002-05-30 Welcher Andrew A. CD20/IgE-receptor like molecules and uses thereof
EA013564B1 (ru) 2000-08-03 2010-06-30 Терапеутик Хьюман Поликлоналз Инк. Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
DOP2006000029A (es) 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
UA107557C2 (xx) 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2012018704A1 (en) 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2663331A4 (en) * 2011-01-10 2015-07-15 Glaxosmithkline Intellectual Property Man Ltd NEW USES
WO2013120012A2 (en) 2012-02-08 2013-08-15 Igm Biosciences Inc. Cdim binding proteins and uses thereof
EP2692343A1 (en) 2012-08-03 2014-02-05 Forward Pharma A/S Combination therapy for treatment of multiple sclerosis
SG11201500499TA (en) 2012-08-10 2015-03-30 Boehringer Ingelheim Int Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
WO2015162504A1 (en) 2014-04-23 2015-10-29 Novartis Ag Novel dosing and uses of ofatumumab
WO2015168103A1 (en) 2014-04-29 2015-11-05 Teva Pharmaceutical Industries Ltd. Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN106699886A (zh) 2015-07-13 2017-05-24 西藏海思科药业集团股份有限公司 抗体依赖性细胞介导的细胞毒性(adcc)增强的奥法木抗体
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
MX2022003010A (es) 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
EP4707302A2 (en) 2020-04-09 2026-03-11 Novartis AG Ofatumumab for treating ms while maintaining serum igg
WO2022219057A1 (en) 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Also Published As

Publication number Publication date
JP6851391B2 (ja) 2021-03-31
IL302488B1 (en) 2024-08-01
KR20200136503A (ko) 2020-12-07
PT3497132T (pt) 2020-09-25
US12570754B2 (en) 2026-03-10
US20220081488A1 (en) 2022-03-17
RS60807B1 (sr) 2020-10-30
CN120053639A (zh) 2025-05-30
US20240150485A1 (en) 2024-05-09
MX388593B (es) 2025-03-20
US20240317878A1 (en) 2024-09-26
JP2020100630A (ja) 2020-07-02
IL264804B (en) 2020-09-30
CN120037367A (zh) 2025-05-27
MX2019001860A (es) 2019-07-08
AU2017311664A1 (en) 2019-01-31
IL276890A (en) 2020-10-29
PT3733712T (pt) 2023-08-31
AU2020201112B2 (en) 2021-07-22
EP4252847A3 (en) 2023-11-15
DK3733712T3 (da) 2023-08-21
AU2017311664B2 (en) 2020-01-02
HUE051948T2 (hu) 2021-03-29
EP4711008A2 (en) 2026-03-18
AU2020201112C1 (en) 2025-05-22
HRP20201388T1 (hr) 2020-11-27
ES2954259T3 (es) 2023-11-21
EP3733712A1 (en) 2020-11-04
PL3497132T3 (pl) 2020-11-30
CN109641965A (zh) 2019-04-16
AU2020201112A1 (en) 2020-03-05
JP2019511506A (ja) 2019-04-25
HRP20230894T1 (hr) 2023-11-24
SI3497132T1 (sl) 2020-10-30
WO2018033841A1 (en) 2018-02-22
AU2017311664C1 (en) 2025-05-22
TWI752995B (zh) 2022-01-21
CA3101514A1 (en) 2018-02-22
IL276890B2 (en) 2023-10-01
IL302488A (en) 2023-06-01
EP4371611A2 (en) 2024-05-22
EP3733712B1 (en) 2023-05-24
IL302488B2 (en) 2024-12-01
CN120000782A (zh) 2025-05-16
ES2821924T3 (es) 2021-04-28
HUE063625T2 (hu) 2024-01-28
IL276890B1 (en) 2023-06-01
RS64541B1 (sr) 2023-09-29
CY1123350T1 (el) 2021-12-31
FI3733712T3 (fi) 2023-08-22
CN120053638A (zh) 2025-05-30
TW201808333A (zh) 2018-03-16
RU2019107146A (ru) 2020-09-15
LT3497132T (lt) 2020-10-12
US20190177424A1 (en) 2019-06-13
PL3733712T3 (pl) 2023-10-16
RU2019107146A3 (da) 2020-09-15
LT3733712T (lt) 2023-09-11
RU2021105514A (ru) 2021-04-19
DE202017007542U1 (de) 2022-07-19
US12338290B2 (en) 2025-06-24
SI3733712T1 (sl) 2023-12-29
EP4252847A2 (en) 2023-10-04
CA3030530C (en) 2021-02-23
EP4371611A3 (en) 2024-07-24
IL313932A (en) 2024-08-01
US11161909B2 (en) 2021-11-02
JP7198786B2 (ja) 2023-01-04
EP3497132A1 (en) 2019-06-19
CA3030530A1 (en) 2018-02-22
EP3497132B1 (en) 2020-06-24
RU2749951C2 (ru) 2021-06-21
US20250289902A1 (en) 2025-09-18
RU2021105514A3 (da) 2022-02-08
KR20190038914A (ko) 2019-04-09

Similar Documents

Publication Publication Date Title
ZA202004919B (en) Anti-tigit antigen-binding proteins and methods of use thereof
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
DK3303386T3 (da) Anti-Tau-antistoffer og fremgangsmåder til anvendlelse
DK3259597T3 (da) Pvrig-polypeptider og fremgangsmåder til behandling
DK3353210T3 (da) Anti-TIGIT-antistoffer og fremgangsmåder til anvendelse
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3096798T3 (da) Plasmakallikreinbindende proteiner og anvendelser deraf til behandling af hereditært angioødem
DK3350201T3 (da) Manipulerede fytaser og fremgangsmåder til anvendelse af samme
DK3638243T3 (da) Fremgangsmåder til behandling af myeloproliferativ neoplasma-forbundet myelofibrose og anæmi
DK3102673T3 (da) Fremgangsmåder og sammensætninger til behandling af beta-talassæmi
DK3377612T3 (da) Funktionel ekspression af monooxygenaser og fremgangsmåder til anvendelse
DK3653221T5 (da) Anti-pvrig-antistoffer og anvendelsesfremgangsmåder
DK3474996T3 (da) Tågeapparat og anvendelsesmåde
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3185868T3 (da) Hidtil ukendte ULK1-inhibitorer og fremgangsmåder til anvendelse af samme
DK3285809T3 (da) Inhibitorer af immunkontrolpunktsmodulatorer til anvendelse i behandling af kræft og infektioner.
DK3242947T3 (da) Genterapi og elektroporese til behandling af maligniteter
DK3514151T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
DK3426777T3 (da) Kombinationsvektorer og fremgangsmåder til behandling af cancer
DK3367852T3 (da) Indretning og fremgangsmåde til behandling af levnedsmidler
IL261653A (en) Ilt7 binding molecules and methods of using the same
DK3261644T3 (da) Sammensætninger og fremgangsmåder til behandling af nethindenedbrydning
DK3368578T3 (da) Anti-HtrA1-antistoffer og fremgangsmåder til anvendelse deraf
DK3463308T3 (da) Formuleringer af polyalkylenoxid-asparaginase og fremgangsmåder til fremstilling og anvendelse deraf